GENinCode inks partnership with DC's MedStar Health
19th Jul 2023 10:42
(Sharecast News) - Predictive generics specialist GENinCode announced a collaboration with MedStar Health on Wednesday - a prominent 10-hospital health system in the Washington, DC area of the United States.
Read moreGENinCode prepares for US revenue as California licence granted
3rd Jan 2023 17:56
(Sharecast News) - Predictive genetics specialist GENinCode announced California state licensing approval and CLIA certification of its Irvine laboratory on Tuesday, enabling it to provide its products for the risk assessment of cardiovascular disease (CVD) to patients across 49 states in the US.
Read moreGENinCode inks collaboration with largest US medical school
23rd Mar 2022 15:31
(Sharecast News) - Cardiovascular genetics company GENinCode announced a collaboration with the Indiana University School of Medicine (IU) on Wednesday - the largest medical school in the United States.
Read moreGENinCode enters cholesterol collaboration with Cumbria health network
15th Mar 2022 13:35
(Sharecast News) - Cardiovascular genetics company GENinCode announced a collaboration with the Academic Health Science Network for the North East and North Cumbria (AHSN NENC) on Tuesday, to pilot the use of its 'Lipid inCode' test for the diagnosis of high cholesterol - hypercholesterolemia - and familial hypercholesterolemia (FH).
Read moreGENinCode reports success in NHS trial of cholesterol test
8th Feb 2022 15:37
(Sharecast News) - Predictive genetics technology company GENinCode announced on Tuesday the successful completion of its NHS clinical study, and positive results for its 'Lipid inCode' test for high cholesterol, including familial hypercholesterolemia (FH), undertaken at Royal Brompton and Harefield Hospitals.
Read moreGenincode moving towards 'a number of important milestones'
25th Nov 2021 11:36
(Sharecast News) - Predictive genetics company Genincode said on Thursday that it was now moving towards "a number of important milestones" which will drive its growth and profile over the coming years.
Read more